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The treatment of nonsevere pregnancy hypertension has been controversial. Although prior randomized controlled 
trials identified that antihypertensive therapy (to normalize 
blood pressure [BP]) was associated with a lower incidence 
of severe hypertension, it was not clear that this was harmful 
in and of itself, particularly when coupled with concerns that 
such therapy could impair fetal growth and increase perinatal 
mortality and morbidity.1
The CHIPS trial (Control of Hypertension in Pregnancy 
Study) has provided evidence that antihypertensive treatment 
of nonsevere hypertension in pregnancy is of benefit to the 
mother, without associated perinatal risk. The CHIPS trial 
Abstract—To determine whether clinical outcomes differed by occurrence of severe hypertension in the international CHIPS 
trial (Control of Hypertension in Pregnancy Study), adjusting for the interventions of “less tight” (target diastolic blood 
pressure [dBP] 100 mm Hg) versus “tight” control (target dBP 85 mm Hg). In this post-hoc analysis of CHIPS data from 
987 women with nonsevere nonproteinuric preexisting or gestational hypertension, mixed effects logistic regression 
was used to compare the following outcomes according to occurrence of severe hypertension, adjusting for allocated 
group and the influence of baseline factors: CHIPS primary (perinatal loss or high-level neonatal care for >48 hours) 
and secondary outcomes (serious maternal complications), birth weight <10th percentile, preeclampsia, delivery at <34 
or <37 weeks, platelets <100×109/L, elevated liver enzymes with symptoms, maternal length of stay ≥10 days, and 
maternal readmission before 6 weeks postpartum. Three hundred and thirty-four (34.1%) women in CHIPS developed 
severe hypertension that was associated with all outcomes examined except for maternal readmission (P=0.20): CHIPS 
primary outcome, birth weight <10th percentile, preeclampsia, preterm delivery, elevated liver enzymes (all P<0.001), 
platelets <100×109/L (P=0.006), and prolonged hospital stay (P=0.03). The association between severe hypertension and 
serious maternal complications was seen only in less tight control (P=0.02). Adjustment for preeclampsia (464, 47.3%) 
did not negate the relationship between severe hypertension and the CHIPS primary outcome (P<0.001), birth weight 
<10th percentile (P=0.005), delivery at <37 (P<0.001) or <34 weeks (P<0.001), or elevated liver enzymes with symptoms 
(P=0.02). Severe hypertension is a risk marker for adverse maternal and perinatal outcomes, independent of BP control 
or preeclampsia co-occurrence.
Clinical Trial Registration—URL: http://pre-empt.cfri.ca/. Unique identifier: ISRCTN 71416914. URL: https://www.
clinicaltrials.gov/. Unique identifier: NCT01192412.   
(Hypertension. 2016;68:1153-1159. DOI: 10.1161/HYPERTENSIONAHA.116.07862.) • Online Data Supplement
Key Words: antihypertensive therapy ■ hypertension ■ labetalol ■ methyldopa ■ pregnancy
Received May 17, 2016; first decision June 10, 2016; revision accepted August 12, 2016.
From the Molecular and Clinical Sciences Research Institute, St. George’s, University of London and St. George’s NHS Hospitals Foundation Trust, 
United Kingdom (L.A.M., P.v.D.); Department of Obstetrics and Gynaecology (L.A.M., P.v.D., J.M.) and School of Population and Public Health (J. Singer), 
University of British Columbia, Canada; Centre for Health Evaluation and Outcome Sciences (CHÉOS), Providence Health Care Research Institute, UBC, 
Vancouver, Canada (T.L.); Medicine and Obstetrics and Gynaecology, University of Montreal, Canada (E.R.); Obstetrics and Gynaecology, University 
of Alberta, Canada (S.R.); Pediatrics (E.A., S.K.L., G.K.), Obstetrics and Gynaecology (E.A., K.E.M.), The Centre for Mother, Infant and Child Research, 
Sunnybrook Research Institute (E.A., K.E.M., J. Sanchez), and Medicine (A.G.L.), University of Toronto, Canada; Clinical Epidemiology and Biostatistics 
(A.G.) and Obstetrics and Gynaecology (E.H.), McMaster University, Canada; Obstetrics and Gynaecology, University of Manitoba, Canada (M.H.); Obstetrics 
and Gynaecology, University of Amsterdam, Netherlands (W.G.); Obstetrics and Gynaecology, Derriford Hospital, United Kingdom (R.W.); Obstetrics and 
Gynaecology, University of Nottingham, United Kingdom (J.G.T.); and Obstetrics and Gynaecology, Universite de Sherbrooke, Canada (J.-M.M.).
*A list of all CHIPS Study Group participants is given in Table S1 in the online-only Data Supplement.
The online-only Data Supplement is available with this article at http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA. 
116.07862/-/DC1.
Correspondence to Laura A. Magee, St George’s, University of London, Cranmer Terrace, Room J 0.27, London SW17 ORE, United Kingdom. E-mail 
LMagee@sgul.ac.uk
© 2016 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article 
under the terms of the Creative Commons Attribution Non-Commercial-NoDervis License, which permits use, distribution, and reproduction in any 
medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
The CHIPS Randomized Controlled Trial (Control  
of Hypertension in Pregnancy Study)
Is Severe Hypertension Just an Elevated Blood Pressure?
Laura A. Magee, Peter von Dadelszen, Joel Singer, Terry Lee, Evelyne Rey, Susan Ross,  
Elizabeth Asztalos, Kellie E. Murphy, Jennifer Menzies, Johanna Sanchez, Amiram Gafni,  
Michael Helewa, Eileen Hutton, Gideon Koren, Shoo K. Lee, Alexander G. Logan,  
Wessel Ganzevoort, Ross Welch, Jim G. Thornton, Jean-Marie Moutquin; for the CHIPS Study Group*
Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.116.07862
Clinical Trial: CHIPS






































































































































































































1154  Hypertension  November 2016
randomized women with nonsevere pregnancy hyperten-
sion to a diastolic blood pressure (dBP) target of 100 mm Hg 
(“less tight” control) versus 85 mm Hg (“tight” control) for a 
planned between-group difference in dBP of 5 mm Hg.2 The 
BP achieved was higher in less tight (versus tight) control by 
a mean of 5.8 mm Hg systolic (95% confidence interval, 4.5–
7.0; 138.8±0.5 mm Hg versus 133.1±0.5 mm Hg; P<0.001) 
and 4.6 mm Hg diastolic (95% confidence interval, 3.7–5.4; 
89.9±0.3 mm Hg versus 85.3±0.3 mm Hg; P<0.001). There 
was no impact of less tight (versus tight) control on perinatal 
death or high-level neonatal care for >48 hours (155, 31.4% in 
less tight versus 150, 30.7% in tight) or serious maternal com-
plications (including death; 18, 3.7% versus 10, 2.0%, respec-
tively). However, there was more severe maternal hypertension 
(200, 40.6% versus 134, 27.5%, respectively), despite almost 
half the women using home BP monitoring (231, 46.5% ver-
sus 225, 46.0%, respectively) and attending frequent antena-
tal visits (ie, a median [interquartile range] of 7.0 [4.0, 11.0] 
clinic visits from a mean gestational age at enrollment of 24 
weeks [23.7±6.3 versus 24.2±6.3 weeks, respectively]). The 
distribution of observed systolic BP and dBP values was simi-
lar between allocated groups, and the excess of severe BP val-
ues in less tight control was not restricted to values just above 
the 160/110 mm Hg diagnostic threshold for severe hyperten-
sion. In addition, predictive modeling did not demonstrate that 
women destined to develop subsequent severe hypertension 
could be identified by clinical characteristics at randomiza-
tion, when a BP management strategy was instituted.3
The CHIPS trial has generated controversy over whether 
the increase in severe hypertension associated with less tight 
control merits a recommendation to use tight control because 
there is disagreement about whether the increased frequency 
of severe hypertension with less tight control: (1) is important 
to prevent because it would otherwise translate into an excess 
of adverse maternal outcomes for which CHIPS was under-
powered to detect; (2) represents any risk to the fetus; or (3) 
can be identified easily and treated promptly in the course of 
antenatal care.3 In this secondary analysis of CHIPS data, we 
sought to examine whether the occurrence of severe hyper-
tension was associated with adverse perinatal and maternal 
outcomes, independent of allocated group and the occurrence 
of preeclampsia, one of the recognized pathways to adverse 
outcomes for hypertensive mothers and their babies.
Methods
In brief, CHIPS was an open pragmatic international multicenter trial 
(ISRCTN 71416914, NCT01192412, http://pre-empt.cfri.ca/CHIPS) 
that was approved by the Research Ethics Board at the University 
of British Columbia as the Coordinating Center (H08-00882) and at 
all study sites. Women at 14+0- to 33+6-week gestation with nonpro-
teinuric preexisting or gestational hypertension, office dBP 90 to 105 
mm Hg (or 85–105 mm Hg if on antihypertensives), and a live fetus 
were randomized (centrally and stratified by center and type of hyper-
tension) to less tight (target dBP 100 mm Hg) or tight control (target 
dBP 85 mm Hg). For additional details, see Appendix in the online-
only Data Supplement.
Women could be recruited on an antihypertensive agent other than 
atenolol from ≥14 weeks’ gestation. Post randomization, labetalol 
was the recommended antihypertensive of first choice, but women 
could stay on their existing antihypertensive agent if they wished or 
if labetalol were contraindicated or unavailable. (The only exceptions 
were atenolol, angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, or direct renin inhibitors.)
The composite primary outcome was pregnancy loss or high-level 
neonatal care for >48 hours in the first 28 days of life, and the sec-
ondary outcome was maternal death or serious maternal complica-
tions before 6 weeks postpartum. Severe hypertension was defined as 
a systolic BP ≥160 mm Hg or a dBP ≥110 mm Hg, measured twice, 
15 minutes apart. Preeclampsia was defined according to Canadian 
clinical practice guidelines4 broadly as the development of new pro-
teinuria or one/more suggestive maternal symptoms (ie, headache, 
visual disturbances, persistent right upper quadrant or epigastric pain, 
severe nausea or vomiting, chest pain, or dyspnea), signs (ie, severe 
hypertension, eclampsia, placental abruption, or pulmonary edema), 
or abnormal laboratory results (ie, elevated aspartate or alanine ami-
notransferase or lactate dehydrogenase [according to local laboratory 
criteria] with symptoms, platelet count <100×109/L, or serum cre-
atinine >2.26 mg/dL [>200 μmol/L]). Further details can be found 
in Table S2 in the online-only Data Supplement and in the CHIPS 
protocol (www.pre-empt.cfri.ca/CHIPS) and in the main CHIPS 
publication.2
Statistical Analysis
Descriptive analyses were undertaken to describe the relationship 
between the occurrence of severe hypertension and the occurrence 
of preeclampsia.
To compare the effect of less tight (versus tight) control among 
women who developed severe hypertension, as opposed to those 
who did not, and the effect of severe hypertension among women 
in less tight, as opposed to those in tight control, a mixed-effects 
logistic regression model was used with an interaction term between 
severe hypertension and allocation group. An additional model with-
out the interaction term was also considered to assess the overall ef-
fect of severe hypertension. We adjusted for the influence of baseline 
factors as in the main CHIPS analysis (ie, stratification factors [hy-
pertension type and center] and key prognostics factors [antihyper-
tensive therapy at randomization, prior BP ≥160/110 mm Hg in this 
pregnancy, gestational age at randomization, region, in-hospital sta-
tus at enrollment, and systolic BP at randomization]) and any others 
that may have differed between those with and those without severe 
hypertension. The same process was undertaken for preeclampsia, 
given the acceptance that it increases maternal and perinatal risk. A 
P value <0.05 was considered statistically significant for the homo-
geneity of the odds ratios (ORs) between women with and without 
each of severe hypertension or preeclampsia, for each of the fol-
lowing adverse outcomes: primary perinatal outcome, secondary 
maternal outcome, severe hypertension, preeclampsia, delivery at 
<37 or 34 weeks, platelet count <100×109/L, elevated aspartate ami-
notransferase or alanine aminotransferase with symptoms, maternal 
length of stay ≥10 days, or maternal readmission before 6 weeks 
postpartum, as applicable.
We further considered the co-occurrence of severe hypertension 
and preeclampsia. These analyses examined the association with 
adverse outcomes for (1) severe hypertension after adjustment for 
preeclampsia, and (2) preeclampsia after adjustment for severe hy-
pertension. A P value <0.05 was considered statistically significant.
All analyses were repeated using a restrictive definition of pre-
eclampsia (ie, the development of new proteinuria, defined as ≥2+ by 
urinary dipstick, ≥0.3 g/d by 24 hours urine collection, or ≥30 mg/
mmol [0.26 mg/mL] urinary creatinine).
Results
For the 981 women randomized and included in the primary 
CHIPS analyses, severe hypertension (N=334, 33.9%) and 
preeclampsia (N=464, 47.3%) were common (Table S3). Most 
women with severe hypertension had preeclampsia (248/334, 
74.5%). Just over half of women with preeclampsia (248/464, 
53.4%) had severe hypertension. No woman had preeclamp-
sia defined only by severe hypertension; one woman had 
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preeclampsia defined only by signs, but she had both severe 
hypertension and placental abruption, another diagnostic 
criterion for preeclampsia.4 Four hundred and thirty women 
(43.8%) had neither severe hypertension nor preeclampsia.
Because women with severe hypertension or preeclamp-
sia were different from those without each of these outcomes 
according to baseline characteristics (Table S4), additional 
adjustments were required to the mixed logistic regression. 
In brief, women who developed severe hypertension were 
more likely to have been randomized to less tight control 
(as previously reported), be non-Caucasian, have had prior 
severe hypertension in the index pregnancy, be taking aspi-
rin at enrollment, and be from regions outside of North and 
South America that had low perinatal mortality ratios. Women 
who developed preeclampsia were randomized at a later ges-
tational age, and were more likely to: have gestational (ver-
sus preexisting) hypertension, have experienced prior severe 
hypertension, be in hospital at enrollment, taking folic acid or 
aprenatal vitamin at enrollment, and have been recruited from 
South America or UK/Europe.
The adjusted OR (aOR) for adverse outcomes in less tight 
versus tight control was similar among women with and those 
without each of severe hypertension and preeclampsia, as 
reflected by the P value for the homogeneity of the OR (Table 
S5). As in the main results overall, women in less tight control 
more frequently developed severe hypertension.
Table 1 shows raw adverse outcome event rates, presented 
according to the occurrence of severe hypertension or pre-
eclampsia. The raw outcome rates are representative as the ORs 
changed little after adjustment. Adverse outcomes appeared to 
be more frequent among women who developed (as opposed 
to those who did not) severe hypertension or preeclampsia. Not 
shown in Table 1 is the apparently lower frequency of adverse 
outcomes among the 85 women with severe hypertension 
without preeclampsia: primary perinatal outcome (23, 27.1%), 
birth weight <10th percentile (14, 16.9%), secondary maternal 
outcome (1, 1.2%), delivery at <37 (26, 31.0%) or <34 weeks 
(9, 10.7%), platelets <100×109/L (0), elevated liver enzymes 
with symptoms (0), and maternal length of stay ≥10 days (0); 
readmission before 6 weeks was similar (5, 6.0%). Adverse 
outcomes appeared to be lower still among the 430 women 
with neither severe hypertension nor preeclampsia: primary 
perinatal outcome (76, 17.7%); birth weight <10th percentile 
(55, 12.9%); secondary maternal outcome (6, 1.4%); delivery 
at <37 weeks (67, 15.6%) or <34 weeks (25, 5.8%); low plate-
lets (0); elevated liver enzymes with symptoms (0); and mater-
nal length of stay ≥10 days (2, 0.5%).
Table 2 presents aORs for adverse outcomes according to 
the occurrence of severe hypertension or preeclampsia.
Development of severe hypertension was associated with 
more adverse perinatal and maternal outcomes. With few 
exceptions, this was true for all women, those within either 
less tight or tight control, and all women following adjust-
ment for the co-occurrence of preeclampsia. Severe hyper-
tension was associated with the secondary maternal outcome 
only in less tight (aOR 3.74; P=0.02) but not tight control 
(aOR 0.94; P=0.93), although the interaction was not statis-
tically significant (P=0.13). A similar pattern was seen for 
maternal readmission before 6 weeks postpartum in less 
tight (aOR 2.26; P=0.06) but not in tight control (aOR 0.88; 
P=0.81), although power was limited with only 44 women 
readmitted, and there was no significant interaction (P=0.17).
Similarly, development of preeclampsia was associated 
with more adverse outcomes. With few exceptions, this was 
true overall, within each of less tight and tight control, and 
overall following additional adjustment for the co-occurrence 
of postrandomization severe hypertension. Preeclampsia was 
associated with the secondary maternal outcome in less tight 
(aOR 5.48; P=0.01) but not tight control (aOR 1.64; P=0.46), 
although there was no significant interaction (P=0.19). A pat-
tern of reduced risk was seen in tight (aOR 0.34; P=0.05) but 
not less tight control (aOR 1.16; P=0.73) for maternal read-
mission before 6 weeks postpartum, although the results did 
not reach statistical significance and there was no significant 
interaction (P=0.07).
New proteinuria was common (N=280, 28.5%; Table 
S3) and present in almost half of women with severe hyper-
tension (162/334, 48.5%). All results were similar to those 
obtained using a broad definition of preeclampsia. In brief, 
after adjustment for baseline differences between women 
with and those without new proteinuria (Table S4), adverse 
outcomes in less tight versus tight control were similar 
among women with and those without new proteinuria 
(Table S5). Adverse outcome rates appeared to be more fre-
quent among women who developed (as opposed to those 
who did not) new proteinuria (Table S6), and development of 
new proteinuria was associated with more adverse perinatal 
and maternal outcomes (Table S7).
Discussion
Main Findings
In the CHIPS trial, women randomized to less tight control 
more frequently developed severe hypertension, and predic-
tive modeling was unable to identify which women were des-
tined to do so.2,3 Both severe hypertension and preeclampsia, 
a recognized risk marker for adverse outcome, were com-
mon (33.9% and 47.3%, respectively) and often developed 
in the same woman (25.3%), but neither severe hypertension 
nor preeclampsia fully accounted for all women with one or 
more of the adverse outcomes considered. However, severe 
hypertension was associated with higher rates of each of the 
CHIPS primary perinatal outcome, birth weight <10th per-
centile, preeclampsia, delivery at <34 or 37 weeks, plate-
lets <100×109/L, elevated liver enzymes with symptoms, 
and maternal length of hospital stay ≥10 days. Only among 
women in less tight control was severe hypertension, which 
also developed more frequently in these women, associated 
with serious maternal complications (the CHIPS secondary 
outcome) and, possibly, maternal readmission within 6 weeks 
postpartum. The negative impact of severe hypertension on 
outcomes was evident even after adjusting for the negative 
effect of preeclampsia.
Strengths and Limitations
Strengths of our study include the multicenter, international 
nature of the CHIPS trial that speaks to the generalizability 
of the results. Our outcome definitions were rigorous, and we 
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were able to define and adjust for preeclampsia defined both 
broadly and narrowly, increasing the relevance of the results to 
settings where preeclampsia is variably defined in guidelines 
or by practitioners.
A limitation of our study is that these analyses were post 
hoc, albeit in response to views that severe hypertension was a 
benign development and not an outcome worthy of avoidance. 
Also, comparisons of women with/without severe hyperten-
sion or preeclampsia, as with all nonrandomized comparisons, 
may reflect the impact of unknown sources of bias related to 
ways that clinicians manage women. Finally, CHIPS as with 
all randomized controlled trials was powered to detect a major 
effect of less tight (versus tight) control of nonsevere hyper-
tension and underpowered to look at interactions.
Table 1. Outcome Rates According to the Occurrence of Postrandomization Severe Hypertension or Preeclampsia (N Women, %)
Outcomes All Women
Severe Hypertension Preeclampsia
Yes No Yes No
1 (pregnancy loss or high-level neonatal 
care for >48 h)
305/981 (31.1%) 156/334 (46.7%) 149/647 (23.0%) 205/464 (44.2%) 99/515 (19.2%)
  Less tight 155/493 (31.4%) 89/200 (44.5%) 66/293 (22.5%) 103/241 (42.7%) 51/250 (20.4%)
  Tight 150/488 (30.7%) 67/134 (50.0%) 83/354 (23.4%) 102/223 (45.7%) 48/265 (18.1%)
Birth weight <10th percentile 175/976 (17.9%) 79/331 (23.9%) 96/645 (14.9%) 104/463 (22.5%) 69/511 (13.5%)
  Less tight 79/490 (16.1%) 43/198 (21.7%) 36/292 (12.3%) 50/240 (20.8%) 27/248 (10.9%)
  Tight 96/486 (19.8%) 36/133 (27.1%) 60/353 (17.0%) 54/223 (24.2%) 42/263 (16.0%)
2 (maternal death or serious complications) 28/981 (2.9%) 16/334 (4.8%) 12/647 (1.9%) 21/464 (4.5%) 7/515 (1.4%)
  Less tight 18/493 (3.7%) 13/200 (6.5%) 5/293 (1.7%) 15/241 (6.2%) 3/250 (1.2%)
  Tight 10/488 (2.0%) 3/134 (2.2%) 7/354 (2.0%) 6/223 (2.7%) 4/265 (1.5%)
Severe hypertension* 334/981 (34.1%) … … 248/464 (53.4%) 85/515 (16.5%)
  Less tight 200/493 (40.6%) … … 149/241 (61.8%) 50/250 (20.0%)
  Tight 134/488 (27.5%) … … 99/223 (44.4%) 35/265 (13.2%)
Preeclampsia† 464/979 (47.4%) 248/333 (74.5%) 216/646 (33.4%) … …
  Less tight 241/491 (49.1%) 149/199 (74.9%) 92/292 (31.5%) … …
  Tight 223/488 (45.7%) 99/134 (73.9%) 124/354 (35.0%) … …
Delivery <37 wk 328/981 (33.4%) 178/332 (53.6%) 150/646 (23.2%) 234/463 (50.5%) 93/513 (18.1%)
  Less tight 175/492 (35.6%) 106/199 (53.3%) 69/293 (23.5%) 123/240 (51.3%) 51/250 (20.4%)
  Tight 153/486 (31.5%) 72/133 (54.1%) 81/353 (22.9%) 111/223 (49.8%) 42/263 (16.0%)
Delivery <34 wk 138/981 (14.1%) 89/332 (26.8%) 49/646 (7.6%) 103/463 (22.2%) 34/513 (6.6%)
  Less tight 77/492 (15.7%) 55/199 (27.6%) 22/293 (7.5%) 60/240 (25.0%) 16/250 (6.4%)
  Tight 61/486 (12.6%) 34/133 (25.6%) 27/353 (7.6%) 43/223 (19.3%) 18/263 (6.8%)
Platelet count <100×109/L 29/981 (3.0%) 19/334 (5.7%) 10/647 (1.5%) 29/464 (6.3%) 0/515 (0.0%)
  Less tight 21/493 (4.3%) 15/200 (7.5%) 6/293 (2.0%) 21/241 (8.7%) 0/250 (0.0%)
  Tight 8/488 (1.6%) 4/134 (3.0%) 4/354 (1.1%) 8/223 (3.6%) 0/265 (0.0%)
Elevated AST or ALT with symptoms 30/980 (3.1%) 22/334 (6.6%) 8/646 (1.2%) 30/464 (6.5%) 0/515 (0.0%)
  Less tight 21/492 (4.3%) 16/200 (8.0%) 5/292 (1.7%) 21/241 (8.7%) 0/250 (0.0%)
  Tight 9/488 (1.8%) 6/134 (4.5%) 3/354 (0.8%) 9/223 (4.0%) 0/265 (0.0%)
Maternal length of stay ≥10 days 17/981 (1.7%) 12/334 (3.6%) 5/647 (0.8%) 15/464 (3.2%) 2/515 (0.4%)
  Less tight 12/493 (2.4%) 9/200 (4.5%) 3/293 (1.0%) 11/241 (4.6%) 1/250 (0.4%)
  Tight 5/488 (1.0%) 3/134 (2.2%) 2/354 (0.6%) 4/223 (1.8%) 1/265 (0.4%)
Readmitted before 6 wk postpartum 44/971 (4.5%) 19/328 (5.8%) 25/643 (3.9%) 18/458 (3.9%) 26/511 (5.1%)
  Less tight 24/488 (4.9%) 14/197 (7.1%) 10/291 (3.4%) 13/237 (5.5%) 11/249 (4.4%)
  Tight 20/483 (4.1%) 5/131 (3.8%) 15/352 (4.3%) 5/221 (2.3%) 15/262 (5.7%)
ALT indicates alanine aminotransferase; and AST, aspartate aminotransferase.
*All women had severe hypertension, and so a breakdown by severe hypertension is not relevant.
†All women with preeclampsia (broadly defined or restricted to new proteinuria) had preeclampsia, and so a breakdown by preeclampsia is not relevant.
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Table 2. Odds Ratios for Adverse Perinatal and Maternal 




OR 95% CI P Value
1 (pregnancy loss or high-level neonatal care for >48 h)
  Severe hypertension (all women) 3.04 2.21 4.18 <0.001
   Only women in less tight control 2.95 1.92 4.52 <0.001
   Only women in tight control 3.15 2.00 4.94 <0.001
   All women, adjusted for 
preeclampsia†
2.16 1.53 3.04 <0.001
  Preeclampsia (all women) 3.16 2.33 4.30 <0.001
   Only women in less tight control 2.88 1.88 4.41 <0.001
   Only women in tight control 3.48 2.26 5.36 <0.001
   All women, adjusted for severe 
hypertension‡
2.54 1.83 3.54 <0.001
Birth weight <10th percentile
  Severe hypertension (all women) 2.06 1.44 2.96 <0.001
   Only women in less tight control 2.23 1.34 3.71 0.002
   Only women in tight control 1.92 1.17 3.14 0.01
   All women, adjusted for 
preeclampsia†
1.75 1.19 2.58 0.005
  Preeclampsia (all women) 1.81 1.28 2.55 <0.001
   Only women in less tight control 2.16 1.29 3.61 0.004
   Only women in tight control 1.57 0.99 2.48 0.06
   All women, adjusted for severe 
hypertension‡
1.50 1.03 2.18 0.03
2 (maternal death or serious complications)
  Severe hypertension (all women) 2.24 0.98 5.11 0.06
   Only women in less tight control 3.74 1.25 11.22 0.02
   Only women in tight control 0.94 0.22 3.93 0.93
   All women, adjusted for 
preeclampsia†
1.60 0.66 3.87 0.30
  Preeclampsia (all women) 3.28 1.34 8.02 0.01
   Only women in less tight control 5.48 1.53 19.59 0.01
   Only women in tight control 1.64 0.44 6.11 0.46
   All women, adjusted for severe 
hypertension‡
2.70 1.03 7.07 0.04
Severe hypertension
  Preeclampsia (all women) 5.85 4.23 8.08 <0.001
   Only women in less tight control 6.04 3.93 9.30 <0.001
   Only women in tight control 5.62 3.50 9.02 <0.001
    (Adjustment for severe 
hypertension not applicable)
… … … …
Preeclampsia
  Severe hypertension (all women) 6.09 4.37 8.49 <0.001
   Only women in less tight control 7.08 4.55 11.00 <0.001
(Continued )
   Only women in tight control 5.15 3.20 8.28 <0.001
   (Adjustment for preeclampsia 
not applicable)
… … … …
Delivery at <37 wk
  Severe hypertension (all women) 3.99 2.88 5.53 <0.001
   Only women in less tight control 4.13 2.68 6.37 <0.001
   Only women in tight control 3.83 2.41 6.08 <0.001
   All women, adjusted for 
preeclampsia†
2.59 1.83 3.68 <0.001
  Preeclampsia (all women) 4.50 3.27 6.18 <0.001
   Only women in less tight control 4.12 2.66 6.36 <0.001
   Only women in tight control 4.94 3.15 7.74 <0.001
   All women, adjusted for severe 
hypertension‡
3.48 2.48 4.90 <0.001
Delivery at <34 wk
  Severe hypertension (all women) 4.38 2.89 6.65 <0.001
   Only women in less tight control 5.09 2.87 9.02 <0.001
   Only women in tight control 3.72 2.06 6.71 <0.001
   All women, adjusted for 
preeclampsia†
3.07 1.97 4.80 <0.001
  Preeclampsia (all women) 3.73 2.42 5.73 <0.001
   Only women in less tight control 4.66 2.53 8.55 <0.001
   Only women in tight control 2.94 1.60 5.40 <0.001
   All women, adjusted for severe 
hypertension‡
2.61 1.63 4.15 <0.001
Platelet count <100×109/L
  Severe hypertension (all women) 3.20 1.39 7.36 0.006
   Only women in less tight control 3.67 1.33 10.15 0.01
   Only women in tight control 2.46 0.58 10.50 0.22
   All women, adjusted for 
preeclampsia†
1.39 0.65 2.97 0.39
  Preeclampsia (all women) 74.05 5.54 990.2 0.001
   Only women in less tight control 52.59 3.76 735.8 0.003
   Only women in tight control 23.13 1.58 338.7 0.02
   All women, adjusted for severe 
hypertension‡
63.29 4.99 803.5 0.001
Elevated AST or ALT with symptoms
  Severe hypertension (all women) 6.12 2.51 14.91 <0.001
   Only women in less tight control 6.13 2.06 18.26 0.001
   Only women in tight control 6.29 1.47 26.95 0.01
   All women, adjusted for 
preeclampsia†
2.47 1.12 5.43 0.02
  Preeclampsia (all women) 73.32 5.48 981.5 0.001
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Interpretation
The CHIPS cohort had a high incidence of adverse outcomes, 
consistent with literature showing a dBP of 90 mm Hg in 
pregnancy identifies a level above which perinatal morbidity 
and other adverse maternal outcomes are increased in non-
proteinuric hypertension.2 Our results are consistent with 
existing randomized controlled trial data that show that less 
tight control is associated with more severe hypertension 
(N=3293 women).5–7 To date, this has been recognized as a 
risk marker for maternal stroke, a rare but devastating (and 
increasing) complication in pregnancy.8,9 Also, our results are 
consistent with a limited literature on the association between 
severe hypertension and adverse outcomes among women 
with chronic hypertension that is severe early in pregnancy5,6 
or after 20 weeks7–9 and among women with severe gesta-
tional hypertension.10,11 However, our study adds to this lit-
erature by demonstrating within the same population that less 
tight control is associated with more severe hypertension, that 
severe hypertension is a risk marker for adverse maternal and 
perinatal outcomes, and that the risks associated with severe 
hypertension are over and above those associated with the co-
occurrence of preeclampsia.
Conclusions
The development of severe hypertension raises concern about 
elevated stroke risk, but the CHIPS data demonstrate that the 
risk of other adverse perinatal and maternal outcomes, includ-
ing serious maternal complications, is also increased, inde-
pendently of the co-occurrence of preeclampsia.
Perspectives
There is more than one pathway that may lead to adverse 
outcomes in hypertensive pregnancy, and women with those 
outcomes may have neither severe hypertension nor pre-
eclampsia, a fact that justifies close antenatal surveillance. 
However, CHIPS data indicate that severe hypertension is 
an outcome worthy of avoidance to minimize maternal and 
perinatal risk. As such, we should move from detection and 
prompt treatment of severe hypertension to prevention. This 
can be achieved with antihypertensive therapy to normalize 
maternal BP, as practiced in the tight BP control arm of the 
CHIPS trial, aiming for a modest dBP of 85 mm Hg. Future 
work should focus on whether one antihypertensive agent 
offers advantages over another.
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   Only women in tight control 24.32 1.67 353.3 0.02
   All women, adjusted for severe 
hypertension‡
54.95 4.28 704.9 0.002
Maternal length of stay ≥10 days
  Severe hypertension (all women) 3.47 1.15 10.44 0.03
   Only women in less tight control 3.64 0.93 14.20 0.06
   Only women in tight control 3.18 0.51 19.92 0.22
   All women, adjusted for 
preeclampsia†
2.01 0.77 5.26 0.15
  Preeclampsia (all women) 6.43 1.93 21.47 0.003
   Only women in less tight control 7.35 1.54 35.04 0.01
   Only women in tight control 3.77 0.69 20.44 0.12
   All women, adjusted for severe 
hypertension‡
4.94 1.45 16.82 0.01
Readmitted before 6 wk postpartum
  Severe hypertension (all women) 1.52 0.80 2.91 0.20
   Only women in less tight  
control
2.26 0.96 5.35 0.06
   Only women in tight control 0.88 0.31 2.52 0.81
   All women, adjusted for 
preeclampsia†
1.91 0.94 3.87 0.07
  Preeclampsia (all women) 0.69 0.37 1.31 0.26
   Only women in less tight  
control
1.16 0.50 2.69 0.73
   Only women in tight control 0.34 0.12 0.98 0.05
   All women, adjusted for severe 
hypertension‡
0.55 0.27 1.10 0.09
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; 
CHIPS, Control of Hypertension in Pregnancy Study; CI, confidence interval; and 
OR, odds ratio.
*The analyses were adjusted for allocation group, as well as stratification 
factors (ie, type of hypertension, center as a random effect) and baseline 
prognostic factors of prior severe hypertension, antihypertensive therapy at 
randomization (yes/no), gestational diabetes mellitus before randomization, and 
gestational age at randomization (categorical) as in the main CHIPS analysis. We 
further adjusted for any other baseline factors (Table S5) that may have differed 
between those with and those without the outcome (ie, severe hypertension, 
preeclampsia). For platelet count, elevated AST/ALT, and maternal length 
of stay, center was not included as an adjustment variable for the analysis 
involving preeclampsia because of low event rate in the without preeclampsia 
group; Firth bias-correction was used in the logistic regression to account for 
the low event rate.
†The effect of severe hypertension, the effect of treatment allocation (ie, less 
tight or tight control), and the effect of preeclampsia did not vary across groups 
defined by the other 2 variables. As such, in the adjustment, the effect of severe 
hypertension was assumed to be the same in the 2 treatment groups and in 
the 2 preeclampsia groups (ie, women with and women without preeclampsia).
‡The effect of preeclampsia, the effect of treatment allocation (ie, less tight 
or tight control), and the effect of severe hypertension did not vary across 
groups defined by the other 2 variables. As such, in the adjustment, the effect 
of preeclampsia was assumed to be the same in the 2 treatment groups and in 
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What Is New?
•	Severe hypertension increases the risk of adverse perinatal and maternal 
outcomes beyond stroke.
•	These risks are independent of the risks of preeclampsia.
What Is Relevant?
•	Severe hypertension is not just a bigger blood pressure. Rather, severe 
hypertension is an important clinical outcome worthy of avoidance.
Summary
Women randomized to less tight control in the CHIPS trial (Control 
of Hypertension in Pregnancy Study) more often developed severe 
hypertension, which could not be predicted from clinical charac-
teristics when hypertension developed. Severe hypertension was 
associated with higher rates of the primary perinatal outcome 
(pregnancy loss or high-level neonatal care for >48 hours), birth 
weight <10th percentile, preeclampsia, preterm delivery, platelets 
<100×109/L, elevated liver enzymes with symptoms, and maternal 
length of hospital stay for ≥10 days. Severe hypertension was as-
sociated with the secondary maternal outcomes (maternal death or 
serious maternal complications) only among women in less tight 
control. Severe hypertension remained a significant risk factor for 
adverse maternal and perinatal outcomes even after adjustment 
for preeclampsia.
Novelty and Significance
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Table S1. CHIPS Study Group 
Steering Committee:  Laura A. Magee (Chair), Elizabeth Asztalos, Amiram Gafni, Andrée 
Gruslin, Michael Helewa, Eileen Hutton, Shoo Lee, Alexander Logan, Jennifer Menzies, Jean-
Marie Moutquin, Kellie Murphy, Evelyne Rey, Sue Ross, Johanna Sanchez, Joel Singer, Peter 
von Dadelszen  
Working Group:  Laura A. Magee (Chair), Elizabeth Asztalos, Peter von Dadelszen, Trinh Hoac, 
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Adjudication Committee:  Laura A. Magee (Chair), Elizabeth Asztalos, Kellie Murphy, Evelyne 
Rey, Peter von Dadelszen  
Data Safety Monitoring Board:  Michael B. Bracken (Chair), Patricia Crowley, Lelia Duley, 
Richard Ehrenkranz, Kevin Thorpe  
Data programmers and analysts:  Sunny Chan, Michael Shi, Shelley Yu  
Collaborators: The number of women recruited in each country and centre is specified in 
brackets. 
ARGENTINA (36): 
Hospital LC Lagomaggiore, Mendoza (16):  Raquel de Lourdes Martin, Maria Florencia Bassi, 
Mirta Clara Caruso, Valeria Lagunas, Fernando Vera 
Hospital Avellaneda, Tucuman (10):  Maria Mohedano de Duhalde, Alicia Beatriz Roque, 
Patricia Roldan, Esteban Marcos Duhalde, Viviana Dip 
Hospital JR Vidal, Corrientes (8):  Jesus Daniel Aguirre, Elba Mirta Alicia Morales, Griselda 
Itati Abreo, Teresa De Sagastizabal, Carolina Gomez, Nadia Rizzi  
Hospital JM Cullen, Santa Fe (2):  Carlos Arias, Ricardo Antonio Bruno   
AUSTRALIA (85): 
Ipswich Hospital, Ipswich (36):  Kassam Mahomed, Alison Drew, Ann Green, Jane Hoare 
Women's and Children's Hospital, Adelaide (18):  Bill Hague, Suzette Coat, Caroline 
Crowther, Peter Muller , Sophie Trenowden 
King Edward Memorial Hospital, Subiaco (17):  Barry Walters, Claire Parker, Dorothy 
Graham, Craig Pennell, Eileen Sung  
Campbelltown Hospital, Penrith South (8):  Angela Makris, Gaksoo Lee, Charlene Thornton, 
Annemarie Hennessy  
Liverpool Hospital, Penrith South (5):  Angela Makris, Gaksoo Lee, Charlene Thornton, 
Annemarie Hennessy 






Maternidade de Vila Nova Cachoeirinha, Sao Paulo (7):  Nelson Sass, Henri Korkes, Dayana 
Couto Ferreira  
Hospital Universitario Antonio Pedro, Niteroi (6):  Renato Augusto Moreira de Sa, Monique 
Schmidt Marques Abreu  
Maternidade Escola da UFRJ, Rio de Janeiro (4):  Rita Guerios Bornia, Nancy Ribeiro da Silva, 
Fernanda Freitas Oliveira Cardoso  
Hospital Sao Lucas - PUCRS, Porto Alegre (2):  Caio Coelho Marques, Jorge Hornos, Ricardo 
Leal Davdt, Letícia Germany Paula, Pedro Luis Zanella  
CANADA (233): 
British Columbia Women's Hospital and Health Centre, Vancouver (32):  Laura A. Magee, 
Peter von Dadelszen, Gabrielle Inglis, Ruth Dillon, Ashley Docherty, Anna Hutfield  
Jim Pattison Outpatient Care and Surgery Centre, Surrey (26):  Keith Still, Sayrin Lalji, Tamara 
Van Tent, Chris Hotz, Tracy Messmer  
St Michael's Hospital, Toronto (22):  Joel G. Ray, Howard Berger, Leanne De Souza, Andrea 
Lausman, Tatiana Freire-Lizama, Kate Besel  
Foothills Medical Centre, Calgary (21):  Paul Gibson, Greta Ellsworth, Leslie Miller, T. Lee-Ann 
Hawkins  
Sunnybrook Health Sciences Centre, Toronto (19):  Michelle Hladunewich, Anna Rogowsky, 
Dini Hui, Virginia Collins  
IWK Health Centre, Halifax (19):  Isabelle Delisle, Cora Fanning  
Royal Alexandra Hospital, Edmonton (16):  Nestor Demianczuk, Rshmi Khurana, Winnie Sia, 
Catherine Marnoch, Carmen Young, Cheryl Lux  
CHU Sainte-Justine, Montreal (15):  Evelyne Rey, Sophie Perreault, Valerie Tremblay  
CHUS Fleurimont, Sherbrooke (13):  Jean-Marie Moutquin, Sophie Desindes, Anne-Marie 
Côté, Veronique Dagenais  
Ottawa Hospital Civic Division, Ottawa (13):  Andrée Gruslin, Heather Clark, Elaine O'Shea, 
Ruth Rennicks White  
Mount Sinai Hospital, Toronto (8):  Shital Gandhi, Mary-Jean Martin, Cheryl Brush, Gareth 
Seaward  
Royal University Hospital, Saskatoon (6):  Jill Newstead-Angel, Judy Brandt, Jocelyne Martel, 
Kristine Mytopher, Elise Buschau  
Ottawa Hospital General Division, Ottawa (5):   Andree Gruslin, Erin Keely, Patti Waddell, 
Ruth Rennicks White, Svetlana Shachkina, Alan Karovitch  
St Paul's Hospital, Vancouver (5):  Robert Anderson, Nicole Koenig, Theresa Yong  





London Health Sciences Centre, London (4):  Renato Natale, Laura Kennedy  
Royal Victoria Hospital, Montreal (2): Lucie Opatrny, Lorraine Lavigne  
Regina General Hospital, Regina (1):  George Carson, Sheila Kelly  
Women’s Health Centre, St John's (1):  Joan Crane, Donna Hutchens  
CHILE (57): 
Hospital Dr Sotero del Rio, Puente Alto (45):  Juan Pedro Kusanovic, Christian Figueroa, Karla 
Silva Neculman, Juan Andres Ortiz, Paula Vargas  
Hospital Base Osorno, Osorno (12):  Pedro Ferrand, Jorge Carrillo 
COLOMBIA (36):   
Corporacion Comfenalco Valle - Universidad Libre (20), Clinica Versalles (11), Clinica 
Materno Infantil Farallones (5), Cali:  Rodrigo Cifuentes Borrero, Dahiana Marcela Gallo, 
Luisa Fernanda Moreno  
ESTONIA (19): 
Tartu University Hospital - Women's Clinic, Tartu (19):  Fred Kirss, Kristiina Rull, Anne Kirss  
HUNGARY (5): 
University of Debrecen, Debrecen (5):  Tamas Major, Andrea Fodor, Tunde Bartha  
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Hillel Yaffe Medical Center, Hadera (6):  Mordechai Hallak, Nardin Aslih, Saja Anabousi-
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Ma'ayney Hayeshua Medical Center, Bnei Brak (3):   Linda Harel, Sima Siev  
Nazareth Hospital (EMMS), Nazareth (3):  Marwan Hakim, Christina Simona Khoury, Najla 
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Islamic Hospital, Amman (13):  Mazen El-Zibdeh, Lama Yousef  
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Christchurch Women's Hospital, Christchurch (16):  Ruth Hughes, Di Leishman, Barbra Pullar 
Waitemata Health-North Shore Hospital, Auckland (1):  Matthew Farrant  
POLAND (21): 
Medical University of Gdansk, Gdansk (9):  Malgorzata Swiatkowska-Freund, Krzysztof Preis, 
Anette Aleksandra Traczyk-Los, Anna Partyka, Joanna Preis-Orlikowska, Mariusz Lukaszuk  
Polish Mothers Memorial Hospital, Lodz (9):  Grzegorz Krasomski, Michael Krekora, Anna 





University School of Medical Sciences, Poznan (3):  Grzegorz H. Breborowicz, Anna Dera-
Szymanowska  
THE NETHERLANDS (96): 
Academic Medical Center, Amsterdam (28):  Wessel Ganzevoort, Jannet Bakker, Joost 
Akkermans, Anouk Pels  
OLVG, Amsterdam (13):  Eline van den Akker, Sabine Logtenberg  
UMCU, Utrecht (10):  Steven Koenen, Maartje de Reus, David Borman, Martijn A. Oudijk 
VU Medical Center, Amsterdam (9):  Annemiek Bolte, Viki Verfaille, Bart Graaf  
Maxima Medical Centre, Veldhoven (8):  Martina Porath, Corine Verhoeven, Ben Willem Mol 
UMCG, Groningen (6):  Maureen T.M. Franssen, Lida Ulkeman, Ineke Hamming, Jose H.M. 
Keurentjes, Ina van der Wal  
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Jeroen Bosch Hospital, 's-Hertogenbosch (1):  Ingrid Gaugler-Senden, Marieke Linders  
UNITED KINGDOM (268):   
Guy's & St Thomas' Hospital, London (38):  Catherine Nelson-Piercy, Annette Briley, May 
Ching Soh, Kate Harding, Hayley Tarft  
New Cross Hospital, Wolverhampton (31):  David Churchill, Katherine Cheshire, Julia Icke, 
Mausumi Ghosh  
Nottingham City Hospital, Nottingham (30):  James Thornton, Yvonne Toomassi, Karen  
Barker, Joanne Fisher, Nicky Grace, Amanda  Green, Joanne Gower , Anna Molnar, Shobhana 
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Queen's Medical Centre, Nottingham (22):   James Thornton, George Bugg, Yvette Davis, 
Ruta Desphande, Yvette Gunn, Mohammed Houda, Anna Molnar, Nia Jones 






Liverpool Women's Hospital, Liverpool (16):  Steve A. Walkinshaw , Angela Pascall, Mark 
Clement-Jones, Michelle Dower, Gillian Houghton, Heather Longworth, Tej Purewal  
Bradford Royal Infirmary, Bradford (13):  Derek Tuffnell, Diane Farrar, Jennifer Syson, Gillian 
Butterfield, Vicky Jones, Rebecca Palethorpe, Tracey Germaine  
Leicester Royal Infirmary, Leicester (12):  Marwan Habiba, Debbie Lee 
Wexham Park Hospital, Slough (12):  Olufemi Eniola, Lynne Blake, Jane Khan  
City Hospitals Sunderland NHS Foundation Trust, Sunderland (10):  Helen M. Cameron, Kim 
Hinshaw, Amanda Bargh, Eileen Walton  
South Warwickshire NHS Trust, Warwick (9): Olanrewaju Sorinola, Anna Guy, Zoe D'Souza, 
Rhiannon Gabriel, Jo Williams  
Derriford Hospital, Plymouth (8):  Ross Welch, Heidi Hollands   
York Hospital, York (8):  Olujimi Jibodu, Sara Collier, Pauline Tottie, Claire Oxby, James Dwyer  
Singleton Hospital, Swansea (7):  Franz Majoko, Helen Goldring, Sharon Jones  
Chesterfield Royal Hospital, Chesterfield (6): Janet Cresswell, Louise Underwood, Mary Kelly-
Baxter, Rebecca Robinson  
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (6):  Dilly Anumba, Anne 
Chamberlain, Clare Pye  
St Mary's Hospital, Manchester (6): Clare Tower, Sue Woods, Lisa Horrocks, Fiona Prichard, 
Lynsey Moorhead, Sarah Lee, Louise Stephens , Cara Taylor, Suzanne Thomas, Melissa 
Whitworth, Jenny Myers  
Birmingham Women's Hospital, Birmingham (5):  Ellen Knox, Katie Freitas, Mark Kilby, 
Amanda Cotterill  
Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire (3):  Khalil Abdo, Katrina 
Rigby, Julie Butler, Fiona Crosfill, Sean Hughes, Sanjeev Prashar, Fatimah Soydemir  
The Royal Derby Hospital, Derby (3):  Janet Ashworth, Lorraine Mycock, Jill Smith  
Basildon & Thurrock University Hospital, Basildon (1):  Amaju Ikomi, Kerry Goodsell, Jean 
Byrne, Maxwell Masuku, Alice Pilcher  
USA (70): 
Cooper University Hospital, Camden (13):  Meena Khandelwal, Gunda Simpkins, Michelle 
Iavicoli, Yon Sook Kim, Richard  Fischer, Robin Perry 
Medical University of South Carolina, Charleston (11):  Eugene Y. Chang, Tamara D. 
Saunders, Betty W. Oswald, Kristin D. Zaks  





Yale-New Haven Hospital, New Haven (8):  Anna Sfakianaki, Cheryl Danton, Erin Kustan, Luisa 
Coraluzzi 
Norton Hospital Downtown (7), Norton Suburban Hospital (2), Louisville:  Helen How, 
Christina Waldon 
East Carolina University, Greenville (6):  Jeffrey Livingston, Sherry Jackson, Lisa Greene 
Meriter Hospital, Madison (6):  Dinesh Shah  
Oregon Health & Science University, Portland (5):  Jorge E. Tolosa, Monica Rincon, Leonardo 
Pereira, Amy E.  Lawrence, Janice E.  Snyder 
University of North Carolina, Chapel Hill (4):  D. Michael Armstrong, Teresa Blue, Austin 







Table S2. Definitions of CHIPS outcomes 
Outcome Definition 
Primary perinatal outcome: pregnancy loss or high level neonatal care for >48hr (until 
primary discharge home or 28d of life, whichever was later) 
Pregnancy loss  
Elective 
termination 
With reason specified, including static fetal growth 
Miscarriage Death of a fetus <500g or <20 wks 
Ectopic 
pregnancy 
Pregnancy outside the uterine cavity 
Stillbirth Death of a fetus ≥500g or ≥20 wks 
Neonatal death  
High level 
neonatal care for 
>48 hr 
Defined as greater-than-normal newborn care 
Secondary maternal outcome: one/more serious maternal complications (including death) 
(until primary discharge home or 6 wks postpartum, whichever was later) 
Maternal death  
Stroke Acute neurological event with deficits lasting > 24 hr, not due to a post-
ictal state 
Eclampsia Generalized convulsion in the absence of a history of epilepsy 
Blindness Either retinal or cortical, defined as loss of visual acuity in the presence 
of intact pupillary response to light 
Uncontrolled 
hypertension 
Need for a third parenteral antihypertensive agent (hypertension 
requiring administration of 3 or more different parenteral [intravenous 
or intramuscular] antihypertensive agents within a 12 hour period) 
Inotropic support Use of vasopressors to keep sBP > 90 mm Hg or a MAP > 70 mm Hg 
Pulmonary 
oedema 
Diagnosed clinically with one/more of oxygen saturation < 95%, diuretic 
treatment or x-ray confirmation 
Respiratory failure Intubation, ventilation (either by ETT or non-invasively), or need for > 
50% oxygen for > 1 hr which is not due to Cesarean delivery 
Myocardial 
ischemia or MI 
By characteristic ECG changes and markers of myocardial necrosis 
Hepatic 
dysfunction 
INR>1.2 in the absence of DIC or treatment with warfarin, OR, in the 






hyperbilirubinemia >1.0 mg/dL (or >17 μM)or hypoglycemia <45 mg/dL 




Presence of a blood collection under the hepatic capsule as confirmed 
by imaging or at laparotomy 
Renal failure Serum creatinine >200 µM 
Transfusion  Of any blood product 
Other As detailed, with appropriate information from hospital records 
Severe 
hypertension  
sBP ≥ 160 mm Hg or dBP≥110 mm Hg, measured twice, 15 minutes 
apart 
Pre-eclampsia New proteinuria (≥ 2+ by urinary dipstick, ≥ 30 mg/mmol urinary 
creatinine by spot testing, elevated urinary albumin:creatinine ratio 
according to local criteria, or ≥ 0.3 g/d by 24 hr urine collection) or 
one/more preeclampsia symptoms, signs, and/or abnormal laboratory 
tests 
Symptoms  Headache, visual disturbances, persistent right upper quadrant or 
epigastric pain, severe nausea or vomiting, chest pain, dyspnea 





Elevated aspartate or alanine aminotransferase or lactate 
dehydrogenase (according to local laboratory criteria) with symptoms, 
platelet count <100x109/L, or serum creatinine > 2.26 mg/dL (>200 µM) 
Delivery at <34 
wk 
Delivery at less than 34 weeks and 0 days of pregnancy 
Delivery at <37 
wk 
Delivery at less than 37 weeks and 0 days of pregnancy 
dBP (diastolic blood pressure), DIC (disseminated intravascular coagulation), ETT (endotracheal tube), 

























Severe hypertension       
















Pre-eclampsia*       
















New proteinuria‡       



















* Pre-eclampsia was defined as the development of new proteinuriaⱡ or one/more suggestive 
maternal symptoms (i.e., headache, visual disturbances, persistent right upper quadrant or 
epigastric pain, severe nausea or vomiting, chest pain, or dyspnea), signs (i.e., in addition to 
severe hypertension: eclampsia, placental abruption, or pulmonary edema), or abnormal 
laboratory results [i.e., elevated aspartate or alanine aminotransferase or lactate 
dehydrogenase (according to local laboratory criteria) with symptoms, platelet count 
<100,000x109/L, or serum creatinine > 2.26 mg/dL (>200 µM)]. 
† No woman had pre-eclampsia defined only by severe hypertension.  
‡ New proteinuria was defined as proteinuria ≥2+ by urinary dipstick, ≥0.3 g/d by 24 hr urine 






Table S4. Baseline characteristics prior to randomization according to the post-randomisation occurrence of severe hypertension, 
pre-eclampsia, or new proteinuria (N (%) women unless otherwise stated) 
Baseline 
characteristics 




















357 (55.2) 205 (61.4) 0.063 296 (57.5) 265 (57.1) 0.909 402 (57.3) 160 (57.1) 0.954 
Mother's ethnicity   <0.001   0.224   0.601 
Caucasian 415 (64.1) 195 (58.4)  318 (61.7) 290 (62.5)  432 (61.6) 178 (63.6)  
Black 61 (9.4) 62 (18.6)  55 (10.7) 68 (14.7)  84 (12.0) 39 (13.9)  
Asian 70 (10.8) 37 (11.1)  60 (11.7) 47 (10.1)  83 (11.8) 24 (8.6)  
Hispanic 90 (13.9) 30 (9.0)  71 (13.8) 49 (10.6)  87 (12.4) 33 (11.8)  
Other 11 (1.7) 10 (3.0)  11 (2.1) 10 (2.2)  15 (2.1) 6 (2.1)  
Gestational age (wk)     0.625   0.044   0.024 
140-206 233 (36.0) 114 (34.1)  186 (36.1) 161 (34.7)  260 (37.1) 87 (31.1)  
210-286 205 (31.7) 116 (34.7)  182 (35.3) 138 (29.7)  235 (33.5) 86 (30.7)  
290-336 209 (32.3) 104 (31.1)  147 (28.5) 165 (35.6)  206 (29.4) 107 (38.2)  
Nulliparous 210 (32.5) 119 (35.6) 0.319 169 (32.8) 159 (34.3) 0.631 218 (31.1) 111 (39.6) 0.010 
Type of hypertension   0.371   0.023   0.015 
Pre-existing  477 (73.7) 255 (76.3)  400 (77.7) 331 (71.3)  538 (76.7) 194 (69.3)  
Gestational 170 (26.3) 79 (23.7)  115 (22.3) 133 (28.7)  163 (23.3) 86 (30.7)  
Previous sBP≥160 or 
dBP≥110mmHg in 
this pregnancy 
63 (9.7) 78 (23.4) <0.001 59 (11.5) 82 (17.7) 0.006 89 (12.7) 52 (18.6) 0.018 
Using home BP 
monitoring 
259 (40.0) 119 (35.6) 0.179 212 (41.2) 166 (35.8) 0.084 288 (41.1) 90 (32.1) 0.90 
In hospital at 
enrollment 























Gestational diabetes  46 (7.1) 17 (5.1) 0.221 34 (6.6) 28 (6.0) 0.716 40 (5.7) 23 (8.2) 0.148 
Cigarette smoking  36 (5.6) 27 (8.1) 0.127 28 (5.4) 35 (7.5) 0.180 44 (6.3) 19 (6.8) 0.769 
Other medication           
Aspirin  150 (23.2) 107 (32.0) 0.003 133 (25.8) 124 (26.7) 0.750 179 (25.5) 78 (27.9) 0.455 
Folic acid and/or 
prenatal vitamin 
427 (66.1) 211 (63.2) 0.362 353 (68.7) 284 (61.2) 0.014 469 (67.0) 169 (60.4) 0.049 
PMR of recruiting country  0.014   0.126   0.655 
Low (<10/1000 births) 528 (81.6) 293 (87.7)  422 (81.9) 397 (85.6)  589 (84.0) 232 (82.9)  
High (≥10/1000 
births ) 
119 (18.4) 41 (12.3)  93 (18.1) 67 (14.4)  112 (16.0) 48 (17.1)  
Regions where women were recruited 0.006   0.047   0.045 
Australasia 54 (8.3) 48 (14.4)  40 (7.8) 62 (13.4)  60 (8.6) 42 (15.0)  
Middle East 18 (2.8) 7 (2.1)  15 (2.9) 10 (2.2)  19 (2.7) 6 (2.1)  
North America 207 (32.0) 94 (28.1)  156 (30.3) 144 (31.0)  222 (31.7) 79 (28.2)  
South America  109 (16.8) 38 (11.4)  84 (16.3) 63 (13.6)  103 (14.7) 44 (15.7)  
UK and Europe 259 (40.0) 147 (44.0)  220 (42.7) 185 (39.9)  297 (42.4) 109 (38.9)  

















Mean (SD) 33.3 (5.8) 34.0 (5.8)  33.8 (5.9) 33.2 (5.7)  33.7 (5.7) 33.0 (5.8)  
Range (16.0, 47.3) (18.5, 51.7)  (17.2, 51.7) (16.0, 48.1)  (17.2, 51.7) (16.0, 48.1)  

















Mean (SD) 33.6 (5.8) 34.3 (5.8)  34.1 (5.9) 33.5 (5.7)  34.0 (5.8) 33.3 (5.8)  
Range (16.1, 47.4) (18.9, 51.8)  (17.3, 51.8) (16.1, 48.6)  (17.3, 51.8) (16.1, 48.6)  







































Mean (SD) 164.0 (7.1) 163.8 (7.5)  163.7 (7.2) 164.2 (7.3)  164.0 (7.2) 163.9 (7.3)  
Range (145.0,193.0) (142.2,184.0)  (145.0,183.0) (142.2,193.0)  (144.8,193.0) (142.2,184.0)  

















Mean (SD) 84.2 (22.2) 82.4 (20.8)  83.6 (22.2) 83.6 (21.3)  83.2 (22.3) 84.5 (20.4)  
Range (40.0, 177.8) (45.2, 165.5)  (45.2, 172.3) (40.0, 177.8)  (40.0, 177.8) (48.0, 165.5)  

















Mean (SD) 31.2 (7.7) 30.7 (7.2)  31.1 (7.7) 31.0 (7.4)  30.9 (7.7) 31.5 (7.3)  
Range (16.2, 64.6) (18.2, 60.8)  (18.2, 64.6) (16.2, 60.8)  (16.2, 64.6) (19.1, 60.8)  
sBP (mmHg) within 1 wk before randomization <0.001 
 

















Mean (SD) 138.8 (9.7) 142.5 (9.3)  139.1 (9.9) 141.2 (9.5)  139.4 (9.9) 141.9 (9.0)  
Range (110.0,160.0) (110.0, 170.0)  (110.0,166.0) (110.0,170.0)  (110.0,166.0) (110.0,170.0)  
sBP (mmHg) within 1 wk before randomization <0.001   0.039   0.078 
<140 284 (43.9) 92 (27.5)  215 (41.7) 161 (34.7)   286 (40.8) 90 (32.1)  
140-149 247 (38.2) 149 (44.6)  207 (40.2) 188 (40.5)   275 (39.2) 121 (43.2)  
150-159 114 (17.6) 88 (26.3)  90 (17.5) 111 (23.9)   135 (19.3) 67 (23.9)  
≥160 2 (0.3) 5 (1.5)  3 (0.6) 4 (0.9)   5 (0.7) 2 (0.7)  











































Mean (SD) 91.9 (4.7) 93.2 (5.4)  92.1 (5.0) 92.7 (5.0)  92.2 (5.0) 92.9 (4.9)  
Range (60.0, 105.0) (78.0, 110.0)  (60.0, 110.0) (79.0, 108.0)  (60.0, 110.0) (79.0, 108.0)  
dBP (mmHg) within 1 wk before randomization <0.001   0.122   0.174 
<90  130 (20.1) 58 (17.4)  111 (21.6) 77 (16.6)  144 (20.5) 44 (15.7)  
90-94 340 (52.6) 145 (43.4)  253 (49.1) 232 (50.0)  350 (49.9) 135 (48.2)  
95-99 115 (17.8) 69 (20.7)  97 (18.8) 87 (18.8)  125 (17.8) 59 (21.1)  
100-105 62 (9.6) 60 (18.0)  53 (10.3) 67 (14.4)  81 (11.6) 41 (14.6)  
≥106 0 (0.0) 2 (0.6)  1 (0.2) 1 (0.2)  1 (0.1) 1 (0.4)  
 
dBP (diastolic blood pressure), EDD (estimated date of delivery), sBP (systolic blood pressure), PMR (perinatal mortality ratio), wk 
(week) 







Table S5. Relationship between ‘less tight’ vs. ‘tight’ control for each of the adverse 
outcomes examined, according to the occurrence of post-randomization severe 
hypertension, pre-eclampsia, or new proteinuria 





 OR 95% CI P  
Primary outcome      
Severe hypertension     0.83 
Less tight vs. tight (severe hypertension) 0.85 0.53 1.35 0.49  
Less tight vs. tight (without severe 
hypertension) 
0.91 0.61 1.33 0.61 
 
Pre-eclampsia     0.53 
Less tight vs. tight (pre-eclampsia) 0.92 0.62 1.35 0.67  
Less tight vs. tight (without pre-eclampsia) 1.11 0.71 1.74 0.65  
New proteinuria     0.98 
Less tight vs. tight (new proteinuria) 1.02 0.62 1.69 0.94  
Less tight vs. tight (without new 
proteinuria) 
1.03 0.72 1.47 0.88 
 
Birth weight < 10th centile      
Severe hypertension     0.72 
Less tight vs. tight (severe hypertension) 0.75 0.44 1.27 0.28  
Less tight vs. tight (without severe 
hypertension) 
0.64 0.41 1.01 0.06 
 
Pre-eclampsia     0.36 
Less tight vs. tight (pre-eclampsia) 0.87 0.56 1.35 0.53  
Less tight vs. tight (without pre-eclampsia) 0.63 0.37 1.06 0.08  
New proteinuria     0.70 
Less tight vs. tight (new proteinuria) 0.86 0.48 1.54 0.62  
Less tight vs. tight (without new 
proteinuria) 
0.75 0.50 1.13 0.17 
 
Serious maternal complications      
Severe hypertension     0.13 
Less tight vs. tight (severe hypertension) 3.44 0.91 13.08 0.07  
Less tight vs. tight (without severe 
hypertension) 
0.86 0.27 2.77 0.80 
 
Pre-eclampsia     0.19 
Less tight vs. tight (pre-eclampsia) 2.39 0.89 6.44 0.08  
Less tight vs. tight (without pre-eclampsia) 0.72 0.16 3.26 0.67  
New proteinuria     0.08 





Less tight vs. tight (without new 
proteinuria) 
0.95 0.35 2.63 0.92 
 
Severe hypertension      
Pre-eclampsia     0.82 
Less tight vs. tight (pre-eclampsia) 1.88 1.27 2.79 0.002  
Less tight vs. tight (without pre-eclampsia) 1.75 1.07 2.85 0.03  
New proteinuria     0.26 
Less tight vs. tight (new proteinuria) 2.36 1.40 3.99 0.001  
Less tight vs. tight (without new 
proteinuria) 
1.63 1.13 2.36 0.01 
 
Pre-eclampsia      
Severe hypertension     0.32 
Less tight vs. tight (severe hypertension) 1.15 0.68 1.95 0.60  
Less tight vs. tight (without severe 
hypertension) 
0.84 0.59 1.18 0.31 
 
Delivery at <37 weeks      
Severe hypertension     0.81 
Less tight vs. tight (severe hypertension) 1.04 0.65 1.67 0.86  
Less tight vs. tight (without severe 
hypertension) 
0.97 0.66 1.43 0.87 
 
Pre-eclampsia     0.56 
Less tight vs. tight (pre-eclampsia) 1.09 0.73 1.61 0.68  
Less tight vs. tight (without pre-eclampsia) 1.30 0.82 2.08 0.27  
New proteinuria     0.61 
Less tight vs. tight (new proteinuria) 1.07 0.64 1.79 0.79  
Less tight vs. tight (without new 
proteinuria) 
1.26 0.87 1.82 0.21 
 
Delivery at <34 weeks      
Severe hypertension     0.45 
Less tight vs. tight (severe hypertension) 1.22 0.72 2.08 0.46  
Less tight vs. tight (without severe 
hypertension) 
0.89 0.49 1.64 0.71 
 
Pre-eclampsia     0.29 
Less tight vs. tight (pre-eclampsia) 1.40 0.87 2.25 0.16  
Less tight vs. tight (without pre-eclampsia) 0.88 0.43 1.890 0.73  
New proteinuria     0.48 
Less tight vs. tight (new proteinuria) 1.47 0.81 2.66 0.21  
Less tight vs. tight (without new 
proteinuria) 
1.10 0.66 1.83 0.70 
 
Platelet count<100x109/L      
Severe hypertension     0.65 





Less tight vs. tight (without severe 
hypertension) 
1.98 0.54 7.24 0.30 
 
Pre-eclampsia     0.67 
Less tight vs. tight (pre-eclampsia) 2.39 1.08 5.27 0.03  
Less tight vs. tight (without pre-eclampsia) 1.05 0.03 41.37 0.98  
New proteinuria     0.61 
Less tight vs. tight (new proteinuria) 2.00 0.58 6.89 0.27  
Less tight vs. tight (without new 
proteinuria) 
3.11 0.99 9.79 0.05 
 
Elevated AST or ALT with symptoms      
Severe hypertension     0.98 
Less tight vs. tight (severe hypertension) 1.92 0.70 5.26 0.21  
Less tight vs. tight (without severe 
hypertension) 
1.96 0.46 8.45 0.36 
 
Pre-eclampsia     0.70 
Less tight vs. tight (pre-eclampsia) 2.15 1.00 4.62 0.05  
Less tight vs. tight (without pre-eclampsia) 1.03 0.03 40.78 0.99  
New proteinuria     0.23 
Less tight vs. tight (new proteinuria) 1.71 0.66 4.43 0.27  
Less tight vs. tight (without new 
proteinuria) 
7.01 0.87 56.17 0.07 
 
Maternal length of stay ≥10 days      
Severe hypertension     0.91 
Less tight vs. tight (severe hypertension) 2.15 0.55 8.44 0.27  
Less tight vs. tight (without severe 
hypertension) 
1.88 0.31 11.37 0.49 
 
Pre-eclampsia     0.57 
Less tight vs. tight (pre-eclampsia) 2.13 0.77 5.93 0.15  
Less tight vs. tight (without pre-eclampsia) 1.09 0.14 8.51 0.93  
New proteinuria     0.98 
Less tight vs. tight (new proteinuria) 2.07 0.51 8.42 0.31  
Less tight vs. tight (without new 
proteinuria) 
2.13 0.38 11.83 0.39 
 
Re-admitted before 6 weeks postpartum      
Severe hypertension     0.17 
Less tight vs. tight (severe hypertension) 2.03 0.70 5.85 0.19  
Less tight vs. tight (without severe 
hypertension) 
0.79 0.35 1.79 0.57 
 
Pre-eclampsia     0.07 
Less tight vs. tight (pre-eclampsia) 2.54 0.88 7.35 0.08  
Less tight vs. tight (without pre-eclampsia) 0.75 0.33 1.67 0.48  





Less tight vs. tight (new proteinuria) 1.55 0.44 5.51 0.50  
Less tight vs. tight (without new 
proteinuria) 
1.08 0.54 2.20 0.82 
 
* The analyses were adjusted for stratification factors (i.e., type of hypertension, centre as a 
random effect) and baseline prognostic factors of prior severe hypertension, antihypertensive 
therapy at randomization (yes/no), gestational diabetes prior to randomization, and 
gestational age at randomization (categorical) as in the main CHIPS analysis. We further 
adjusted for any other baseline factors (Table S3) that may have differed between those with 








Table S6. Outcome rates according to the occurrence of post-randomization severe hypertension, pre-eclampsia, or new proteinuria 
(N women, %) 
Outcomes All women Severe hypertension Pre-eclampsia New proteinuria 
  Yes No Yes No Yes No 












































































































































‘Less tight’ 200/493  
(40.6%) 








‘Tight’ 134/488  
(27.5%) 





















Outcomes All women Severe hypertension Pre-eclampsia New proteinuria 
  Yes No Yes No Yes No 
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- - - - 
 New  
proteinuria 

















































































































































Outcomes All women Severe hypertension Pre-eclampsia New proteinuria 
  Yes No Yes No Yes No 
Elevated AST 
or ALT with 
symptoms 


































































































































AST (aspartate aminotransferase), ALT (alanine aminotransferase) 
 
* All women had severe hypertension and so a breakdown by severe hypertension is not relevant. 
† All women with pre-eclampsia (broadly defined or restricted to new proteinuria) had pre-eclampsia and so a breakdown by pre-





Table S7. Unadjusted and adjusted analyses, examining the effects of severe hypertension, pre-eclampsia, and new proteinuria on 
adverse outcomes 
 Unadjusted analysis Adjusted analysis* 
Comparison OR 95% CI P OR 95% CI P 
Primary outcome         
Severe hypertension         
With vs. without (all women) 2.98 2.24 3.97 <0.001 3.04 2.21 4.18 <0.001 
With vs. without (within ‘less tight’) 2.76 1.87 4.08 <0.001 2.95 1.92 4.52 <0.001 
With vs. without (within ‘tight’) 3.27 2.15 4.96 <0.001 3.15 2.00 4.94 <0.001 
With vs. without (all women, adjusted for pre-eclampsia†) 2.09 1.53 2.84 <0.001 2.16 1.53 3.04 <0.001 
Pre-eclampsia             
With vs. without (all women) 3.33 2.50 4.43 <0.001 3.16 2.33 4.30 <0.001 
With vs. without (within less tight) 2.91 1.95 4.34 <0.001 2.88 1.88 4.41 <0.001 
With vs. without (within tight) 3.81 2.53 5.74 <0.001 3.48 2.26 5.36 <0.001 
With vs. without (all women, adjusted for severe 
hypertension‡) 
2.58 1.90 3.51 <0.001 2.54 1.83 3.54 <0.001 
New proteinuria             
With vs. without (all women) 2.60 1.95 3.48 <0.001 2.51 1.83 3.44 <0.001 
With vs. without (within less tight) 2.52 1.68 3.78 <0.001 2.50 1.61 3.87 <0.001 
With vs. without (within tight) 2.70 1.78 4.10 <0.001 2.52 1.61 3.95 <0.001 
With vs. without (all women, adjusted for severe 
hypertension§) 
1.99 1.46 2.71 <0.001 2.03 1.45 2.84 <0.001 
Birth weight < 10th centile         
Severe hypertension         
With vs. without (all women) 1.89 1.35 2.65 <0.001 2.06 1.44 2.96 <0.001 
With vs. without (within less tight) 1.97 1.21 3.21 0.006 2.23 1.34 3.71 0.002 
With vs. without (within tight) 1.81 1.13 2.91 0.01 1.92 1.17 3.14 0.01 
With vs. without (all women, adjusted for pre-eclampsia†) 1.57 1.09 2.27 0.02 1.75 1.19 2.58 0.005 
Pre-eclampsia             





 Unadjusted analysis Adjusted analysis* 
Comparison OR 95% CI P OR 95% CI P 
With vs. without (within less tight) 2.15 1.30 3.58 0.003 2.16 1.29 3.61 0.004 
With vs. without (within tight) 1.68 1.07 2.64 0.02 1.57 0.99 2.48 0.06 
With vs. without (all women, adjusted for severe 
hypertension‡) 
1.59 1.10 2.29 0.01 1.50 1.03 2.18 0.03 
New proteinuria             
With vs. without (all women) 1.49 1.05 2.11 0.024 1.42 0.99 2.03 0.06 
With vs. without (within less tight) 1.54 0.93 2.54 0.093 1.53 0.91 2.56 0.11 
With vs. without (within tight) 1.45 0.90 2.35 0.130 1.33 0.81 2.17 0.26 
With vs. without (all women, adjusted for severe 
hypertension§) 
1.24 0.86 1.79 0.25 1.21 0.83 1.77 0.33 
Serious maternal complications         
Severe hypertension         
With vs. without (all women) 2.50 1.16 5.38 0.02 2.24 0.98 5.11 0.06 
With vs. without (within less tight) 4.00 1.40 11.42 0.009 3.74 1.25 11.22 0.02 
With vs. without (within tight) 1.14 0.29 4.46 0.86 0.94 0.22 3.93 0.93 
With vs. without (all women, adjusted for pre-eclampsia†) 1.69 0.76 3.76 0.20 1.60 0.66 3.87 0.30 
Pre-eclampsia             
With vs. without (all women) 3.38 1.42 8.04 0.006 3.28 1.34 8.02 0.01 
With vs. without (within less tight) 5.46 1.56 19.12 0.008 5.48 1.53 19.59 0.01 
With vs. without (within tight) 1.80 0.50 6.48 0.37 1.64 0.44 6.11 0.46 
With vs. without (all women, adjusted for severe 
hypertension‡) 
2.63 1.08 6.42 0.03 2.70 1.03 7.07 0.04 
New proteinuria             
With vs. without (all women) 1.88 0.88 4.03 0.11 1.85 0.83 4.14 0.13 
With vs. without (within less tight) 3.05 1.18 7.90 0.02 3.31 1.21 9.06 0.02 
With vs. without (within tight) 0.67 0.14 3.19 0.61 0.62 0.12 3.11 0.56 
With vs. without (all women, adjusted for severe 
hypertension§) 
1.43 0.63 3.22 0.39 1.50 0.63 3.54 0.36 





 Unadjusted analysis Adjusted analysis* 
Comparison OR 95% CI P OR 95% CI P 
Pre-eclampsia         
With vs. without (all women) 5.89 4.37 7.95 <0.001 5.85 4.23 8.08 <0.001 
With vs. without (within less tight) 6.48 4.32 9.71 <0.001 6.04 3.93 9.30 <0.001 
With vs. without (within tight) 5.25 3.37 8.17 <0.001 5.62 3.50 9.02 <0.001 
Adjustment for severe hypertension not applicable - - - - - - - - 
New proteinuria             
With vs. without (all women) 4.26 3.17 5.73 <0.001 4.21 3.04 5.83 <0.001 
With vs. without (within less tight) 5.34 3.52 8.11 <0.001 5.03 3.20 7.91 <0.001 
With vs. without (within tight) 3.33 2.17 5.11 <0.001 3.48 2.19 5.54 <0.001 
Adjustment for severe hypertension not applicable - - - - - - - - 
Pre-eclampsia         
Severe hypertension         
With vs. without (all women) 5.89 4.37 7.95 <0.001 6.09 4.37 8.49 <0.001 
With vs. without (within less tight) 6.48 4.32 9.71 <0.001 7.08 4.55 11.00 <0.001 
With vs. without (within tight) 5.25 3.37 8.17 <0.001 5.15 3.20 8.28 <0.001 
Adjustment for pre-eclampsia or new proteinuria not 
applicable 
- - - - - - - - 
Delivery at <37 weeks         
Severe hypertension         
With vs. without (all women) 3.82 2.87 5.08 <0.001 3.99 2.88 5.53 <0.001 
With vs. without (within less tight) 3.70 2.51 5.45 <0.001 4.13 2.68 6.37 <0.001 
With vs. without (within tight) 3.96 2.60 6.04 <0.001 3.83 2.41 6.08 <0.001 
With vs. without (all women, adjusted for pre-
eclampsia†) 
2.47 1.82 3.37 <0.001 2.59 1.83 3.68 <0.001 
Pre-eclampsia             
With vs. without (all women) 4.60 3.45 6.15 <0.001 4.50 3.27 6.18 <0.001 
With vs. without (within less tight) 4.10 2.75 6.11 <0.001 4.12 2.66 6.36 <0.001 





 Unadjusted analysis Adjusted analysis* 
Comparison OR 95% CI P OR 95% CI P 
With vs. without (all women, adjusted for severe 
hypertension‡) 
3.42 2.52 4.65 <0.001 3.48 2.48 4.90 <0.001 
New proteinuria             
With vs. without (all women) 4.43 3.30 5.95 <0.001 4.36 3.14 6.04 <0.001 
With vs. without (within less tight) 4.06 2.70 6.09 <0.001 4.03 2.58 6.29 <0.001 
With vs. without (within tight) 4.88 3.18 7.49 <0.001 4.74 2.98 7.52 <0.001 
With vs. without (all women, adjusted for severe 
hypertension§) 
3.37 2.47 4.59 <0.001 3.50 2.48 4.94 <0.001 
Delivery at <34 weeks         
Severe hypertension         
With vs. without (all women) 4.43 3.02 6.49 <0.001 4.38 2.89 6.65 <0.001 
With vs. without (within less tight) 4.70 2.76 8.03 <0.001 5.09 2.87 9.02 <0.001 
With vs. without (within tight) 4.15 2.39 7.21 <0.001 3.72 2.06 6.71 <0.001 
With vs. without (all women, adjusted for pre-
eclampsia†) 
3.07 2.04 4.64 <0.001 3.07 1.97 4.80 <0.001 
Pre-eclampsia             
With vs. without (all women) 4.01 2.66 6.05 <0.001 3.73 2.42 5.73 <0.001 
With vs. without (within less tight) 4.87 2.72 8.75 <0.001 4.66 2.53 8.55 <0.001 
With vs. without (within tight) 3.25 1.82 5.82 <0.001 2.94 1.60 5.40 <0.001 
With vs. without (all women, adjusted for severe 
hypertension‡) 
2.66 1.71 4.13 <0.001 2.61 1.63 4.15 <0.001 
New proteinuria             
With vs. without (all women) 2.78 1.92 4.02 <0.001 2.64 1.78 3.92 <0.001 
With vs. without (within less tight) 3.11 1.89 5.12 <0.001 3.01 1.77 5.13 <0.001 
With vs. without (within tight) 2.42 1.39 4.20 0.002 2.27 1.27 4.05 0.006 
With vs. without (all women, adjusted for severe 
hypertension§) 
1.86 1.25 2.76 0.002 1.88 1.23 2.87 0.004 
Platelet count<100x109/L         





 Unadjusted analysis Adjusted analysis* 
Comparison OR 95% CI P OR 95% CI P 
With vs. without (all women) 3.46 1.58 7.57 0.002 3.20 1.39 7.36 0.006 
With vs. without (within less tight) 3.88 1.48 10.18 0.006 3.67 1.33 10.15 0.01 
With vs. without (within tight) 2.69 0.66 10.92 0.17 2.46 0.58 10.50 0.22 
With vs. without (all women, adjusted for pre-eclampsia†) 1.45 0.67 3.16 0.34 1.39 0.65 2.97 0.39 
Pre-eclampsia         
With vs. without (all women) 68.37 4.26 1096.6 0.003 74.05 5.54 990.2 0.001 
With vs. without (within less tight) 48.85 2.93 815.7 0.007 52.59 3.76 735.8 0.003 
With vs. without (within tight) 20.94 1.20 366.9 0.04 23.13 1.58 338.7 0.02 
With vs. without (all women, adjusted for severe 
hypertension‡) 
59.11 3.69 947.2 0.004 63.29 4.99 803.5 0.001 
New proteinuria         
With vs. without (all women) 2.03 0.96 4.28 0.06 2.13 0.98 4.65 0.06 
With vs. without (within less tight) 1.80 0.74 4.36 0.20 1.88 0.75 4.73 0.18 
With vs. without (within tight) 2.75 0.68 11.16 0.16 2.92 0.70 12.13 0.14 
With vs. without (all women, adjusted for severe 
hypertension§) 
1.37 0.62 3.03 0.44 1.52 0.66 3.53 0.33 
Elevated AST or ALT with symptoms         
Severe hypertension         
With vs. without (all women) 5.16 2.26 11.79 <0.001 6.12 2.51 14.91 <0.001 
With vs. without (within less tight) 4.99 1.80 13.86 0.002 6.13 2.06 18.26 0.001 
With vs. without (within tight) 5.48 1.35 22.25 0.02 6.29 1.47 26.95 0.01 
With vs. without (all women, adjusted for pre-eclampsia†) 2.18 0.97 4.90 0.06 2.47 1.12 5.43 0.02 
Pre-eclampsia         
With vs. without (all women) 70.93 4.42 1137.2 0.003 73.32 5.48 981.5 0.001 
With vs. without (within less tight) 48.85 2.93 815.7 0.007 50.60 3.61 708.9 0.004 
With vs. without (within tight) 23.52 1.35 408.6 0.03 24.32 1.67 353.3 0.02 
With vs. without (all women, adjusted for severe 
hypertension‡) 
51.99 3.26 829.5 0.005 54.95 4.28 704.9 0.002 





 Unadjusted analysis Adjusted analysis* 
Comparison OR 95% CI P OR 95% CI P 
With vs. without (all women) 7.24 3.18 16.49 <0.001 8.07 3.42 19.08 <0.001 
With vs. without (within less tight) 5.03 1.99 12.74 <0.001 5.80 2.19 15.36 <0.001 
With vs. without (within tight) 22.90 2.84 184.9 0.003 23.80 2.95 191.76 0.003 
With vs. without (all women, adjusted for severe 
hypertension§) 
5.01 2.11 11.91 <0.001 6.16 2.45 15.47 <0.001 
Maternal length of stay ≥10 days         
Severe hypertension         
With vs. without (all women) 4.37 1.51 12.61 0.006 3.47 1.15 10.44 0.03 
With vs. without (within less tight) 4.56 1.22 17.04 0.02 3.64 0.93 14.20 0.06 
With vs. without (within tight) 4.03 0.67 24.39 0.13 3.18 0.51 19.92 0.22 
With vs. without (all women, adjusted for pre-eclampsia†) 2.32 0.82 6.60 0.11 2.01 0.77 5.26 0.15 
Pre-eclampsia         
With vs. without (all women) 6.92 1.84 26.03 0.004 6.43 1.93 21.47 0.003 
With vs. without (within less tight) 8.30 1.49 46.08 0.02 7.35 1.54 35.04 0.01 
With vs. without (within tight) 3.62 0.56 23.23 0.18 3.77 0.69 20.44 0.12 
With vs. without (all women, adjusted for severe 
hypertension‡) 
4.90 1.24 19.34 0.02 4.94 1.45 16.82 0.01 
New proteinuria         
With vs. without (all women) 4.62 1.69 12.65 0.003 3.70 1.29 10.60 0.01 
With vs. without (within less tight) 4.87 1.44 16.44 0.01 3.67 1.02 13.21 0.05 
With vs. without (within tight) 4.12 0.68 24.91 0.12 3.77 0.61 23.35 0.15 
With vs. without (all women, adjusted for severe 
hypertension§) 
3.21 1.10 9.32 0.03 2.79 0.90 8.63 0.07 
Re-admitted before 6 weeks postpartum         
Severe hypertension         
With vs. without (all women) 1.49 0.80 2.77 0.20 1.52 0.80 2.91 0.20 
With vs. without (within less tight) 2.15 0.94 4.94 0.07 2.26 0.96 5.35 0.06 
With vs. without (within tight) 0.89 0.32 2.50 0.83 0.88 0.31 2.52 0.81 





 Unadjusted analysis Adjusted analysis* 
Comparison OR 95% CI P OR 95% CI P 
Pre-eclampsia         
With vs. without (all women) 0.77 0.42 1.40 0.39 0.69 0.37 1.31 0.26 
With vs. without (within less tight) 1.25 0.56 2.80 0.59 1.16 0.50 2.69 0.73 
With vs. without (within tight) 0.41 0.15 1.09 0.07 0.34 0.12 0.98 0.05 
With vs. without (all women, adjusted for severe 
hypertension‡) 
0.60 0.31 1.17 0.13 0.55 0.27 1.10 0.09 
New proteinuria         
With vs. without (all women) 0.83 0.41 1.66 0.59 0.78 0.38 1.61 0.50 
With vs. without (within less tight) 0.96 0.39 2.37 0.93 0.91 0.36 2.30 0.84 
With vs. without (within tight) 0.67 0.22 2.04 0.48 0.64 0.21 1.97 0.43 
With vs. without (all women, adjusted for severe 
hypertension§) 
0.70 0.33 1.45 0.33 0.67 0.32 1.42 0.30 
 
* The analyses were adjusted for allocation group, as well as stratification factors (i.e., type of hypertension, centre as a random 
effect) and baseline prognostic factors of prior severe hypertension, antihypertensive therapy at randomization (yes/no), 
gestational diabetes prior to randomisation, and gestational age at randomisation (categorical) as in the main CHIPS analysis. We 
further adjusted for any other baseline factors (Table S5) that may have differed between those with and those without the 
outcome (i.e., severe hypertension, pre-eclampsia, or new proteinuria).   For platelet count, elevated AST/ALT and maternal 
length of stay, centre was not included as an adjustment variable for the analysis involving pre-eclampsia due to low event rate in 
the without pre-eclampsia group; Firth bias-correction was employed in the logistic regression to account for the low event rate. 
Those adjusted analyses significant at the p<0.05 level are highlighted in yellow.  
† The effect of severe hypertension, the effect of treatment allocation (i.e., ‘less tight’ or ‘tight’ control), and the effect of pre-
eclampsia did not vary across groups defined by the other two variables. As such, in the adjustment, the effect of severe 
hypertension was assumed to be the same in the two treatment groups and in the two pre-eclampsia groups (i.e., women with 
and women without pre-eclampsia). 
‡ The effect of pre-eclampsia, the effect of treatment allocation (i.e., ‘less tight’ or ‘tight’ control), and the effect of severe 





was assumed to be the same in the two treatment groups and in the two severe hypertension groups (i.e., women with and 
women without severe hypertension). 
§ The effect of new proteinuria, the effect of treatment allocation (i.e., ‘less tight’ or ‘tight’ control), and the effect of severe 
hypertension did not vary across groups defined by the other two variables. As such, in the adjustment, the effect of new 
proteinuria was assumed to be the same in the two treatment groups and in the two severe hypertension groups (i.e., women with 
and women without severe hypertension). 
 
